TỶ LỆ TÁI PHÁT CỦA UNG THƯ BIỂU MÔ BUỒNG TRỨNG GIAI ĐOẠN SỚM ĐIỀU TRỊ BẰNG PHÁC ĐỒ CARBOPLATIN – PACLITAXEL SAU 5 NĂM TẠI BỆNH VIỆN TỪ DŨ

Abstract

Background: According to Globocan 2012, ovarian cancer in Vietnam ranks 11th among female cancers, with an age-standardized incidence rate of 2.6/100,000 women ^[1]. The two main methods of treating cervical cancer are surgical staging and chemotherapy. For early-stage epithelial ovarian cancer, the Paclitaxel – Carboplatin regimen is one of the regimens used as an adjunct after surgical staging when indicated. In this study, we focus on the group of patients with epithelial ovarian cancer. (EOC). Objective: To determine the 5-year recurrence rate of early-stage EOC treated with the Paclitaxel – Carboplatin regimen. Methods: Retrospective cross sectional study, conducted on 200 patients with EOC stages I, IIA who were treated with the Carboplatin - Paclitaxel regimen for at least 3 cycles, without other accompanying cancers from 2012 - 2017 at Tu Du Hospital. Results: The recurrence rate of EOC after 5 years after treatment with Paclitaxel - Carboplatin regimen at Tu Du Hospital was 13.0% (95% CI: 8.5 - 18.0). The survival rate after 5 years is 87%. The factor related to the recurrence rate is the histological grade: grade 3 has a higher risk of recurrence than grade 1 with OR 3.25 (95% CI 1.02 - 11.11). Conclusion: The effectiveness of Paclitaxel - Carboplatin regimen is used as an adjunct after surgical staging for early-stage EOC when indicated to help increase the survival rate, reduce the patient's recurrence and metastasis rate. In addition, clinicians need to consider close follow-up in cases of histological grade 3 when patients go for follow-up examinations to detect early recurrence of lesions at an early age, helping to improve the patient's survival.